IP Library › Granted Patent US 12,472,249
Granted Patent B2
US 12,472,249 · App. 18/742,842 · Granted Nov 18, 2025

Glyconjugate vaccines

Inventors: Brendan Wren (London, GB); Jeremy Brown (London, GB); Jon Cuccui (London, GB)
Assignees: UCL Business LTD; London School of Hygiene & Tropical Medicine
A61K39/385A61K39/092A61K47/646C07K14/3156C12P21/005A61K2039/6087
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 12,472,249
App. No.
18/742,842
Granted
Nov 18, 2025
Kind
B2
Abstract

This invention relates to the use of S. pneumoniae protein antigens, such as NanA, PiuA and Sp0148, as carriers for immunogenic S. pneumoniae capsular polysaccharide. This may be useful for example in glycoconjugate vaccines able to generate a protective immune response against multiple capsular serotypes. Glycoconjugates, vaccine compositions and methods of manufacture and use are provided.

Claims (7)

1 . A glycoconjugate comprising an isolated S. pneumoniae protein antigen glycosylated with an isolated S. pneumoniae capsular polysaccharide, wherein the isolated protein antigen is S. pneumoniae Sp0148 protein antigen comprising an amino acid sequence having at least 80% sequence identity to SEQ ID NO: 9.

2 . The glycoconjugate according to claim 1 , wherein the Sp0148 protein antigen comprises a heterologous glycosylation sequon comprising the sequence D/E-Y-N-X-S/T, wherein Y and X are any amino acid except proline.

3 . The glycoconjugate according to claim 2 , wherein the protein antigen comprising the heterologous glycosylation sequon comprises an amino acid sequence having at least 80% sequence identity to the amino acid sequence of SEQ ID NO: 8.

4 . The glycoconjugate according to claim 2 , wherein the protein antigen comprises two or more of the heterologous glycosylation sequons.

5 . The glycoconjugate according to claim 1 , wherein the capsular polysaccharide is S. pneumoniae serotype 4 capsular polysaccharide.

6 . A composition comprising the glycoconjugate according to claim 1 and a pharmaceutically acceptable excipient.

7 . The composition according to claim 6 further comprising an adjuvant.

Assignments (1)
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Jun 27, 2025
From: CUCCUI, JON; WREN, BRENDAN
To: LONDON SCHOOL OF HYGIENE & TROPICAL MEDICINE
Reel/Frame 071549/0734 →
Priority Claims (1)
EP 1807303 · May 3, 2018 · regional
Continuity (2)
Division 17052485
Related Publication 20240382585A1 · Nov 21, 2024
References Cited (16)
US 11576958B2 · Malley et al. · 2023 [cited by applicant]
US 20120135037A1 · Mizel et al. · 2012 [cited by applicant]
WO 2006032499A1 · 2006 [cited by applicant]
WO 2017216286A1 · 2017 [cited by applicant]
Brendan Wren: “Development of low cost recombinant glycoconjugate vaccines”, Nov. 26, 2018 (Nov. 26, 2018), XP055612404, Retrieved from the Internet: URL:https://www.tm.mahidol.ac.th/research/News&Events/ 2018_ 11_26/20… [cited by applicant]
Emily J. Kay et al: “Recombinant expression of [cited by applicant]
J. Cuccui et al: “Exploitation of bacterial N-linked glycosylation to develop a novel recombinant glycoconjugate vaccine against Francisella tularensis”, The Journal of Infectious Diseases, vol. 205, No. 7, May 22, 2013… [cited by applicant]
J. S. Brown et al: “Immunization with Components of Two Iron Uptake ABC Transporters Protects Mice against Systemic [cited by applicant]
Jomaa et al. “Antibodies to the Iron Uptake ABC Transporter Lipoproteins PiaA and PiuA Promote Opsonophagocytosis of [cited by applicant]
Jon Cuccui et al: “Hijacking bacterial glycosylation for the production of glycoconjugates, from vaccines to humanised glycoproteins”, Journal of Pharmacy and Pharmacology, vol. 67, No. 3, Sep. 22, 2014 (Sep. 22, 2014),… [cited by applicant]
Kuo et al: “Characterization of a recombinant pneumolysin and its use as a protein carrier for pneumococcal type 18C conjugate vaccines.”, Infection and Immunity, vol. 63, No. 7, Jul. 1, 1995 (Jul. 1, 1995), pp. 2706-27… [cited by applicant]
Mark Reglinski et al: “A recombinant conjugated pneumococcal vaccine that protects against murine infections with a similar efficacy to Prevnar-13”, Npj Vaccines, vol. 3, No. 1, Oct. 31, 2018 (Oct. 31, 2018), XP05561240… [cited by applicant]
PCT International Search Report with International Application No. PCT/EP2019/061266, Filing date: May 2, 2019, pp. 1-6. [cited by applicant]
PCT Written Opinion of the International Searching Authority, International Application No. PCT/EP2019/061266, Filing date May 2, 2019, pp. 1-12. [cited by applicant]
Wacker Michael et al: “Prevention of [cited by applicant]
Whalan et al. “PiuA and PiaA, iron uptake lipoproteins of [cited by applicant]